We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 18 of 340 for:    "Muscular Dystrophies"

The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2009 by GAAD Medical Research Institute Inc..
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00674843
First Posted: May 8, 2008
Last Update Posted: August 17, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
GAAD Medical Research Institute Inc.
  Purpose
The muscular dystrophies (MD) are a group of more than 30 neuromuscular disorders that are characterized by progressive skeletal muscle weakness, defects in muscle proteins and the death of muscle cells and tissue. This study will investigate the use of far infrared radiation for managing muscular dystrophies.

Condition Intervention Phase
Muscular Dystrophies Radiation: Far Infrared Radiation Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation to Manage or Treat Muscular Dystrophies.

Resource links provided by NLM:


Further study details as provided by GAAD Medical Research Institute Inc.:

Primary Outcome Measures:
  • Management and Cure of muscular dystrophies [ Time Frame: 2 Years ]

Secondary Outcome Measures:
  • Rehabilitation of people with muscular dystrophies [ Time Frame: 2 Years ]

Enrollment: 4
Study Start Date: May 2008
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Radiation: Far Infrared Radiation
Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.

Detailed Description:

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly cure these neuromuscular disorders.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Persons with muscular dystrophies

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00674843


Locations
Canada, Ontario
The Centre for Incurable Diseases
Toronto, Ontario, Canada, M4V 1L5
Sponsors and Collaborators
GAAD Medical Research Institute Inc.
Investigators
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
  More Information

Responsible Party: Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier: NCT00674843     History of Changes
Other Study ID Numbers: GAAD-MD-CTP1
First Submitted: May 6, 2008
First Posted: May 8, 2008
Last Update Posted: August 17, 2009
Last Verified: August 2009

Keywords provided by GAAD Medical Research Institute Inc.:
MYOTONIC DYSTROPHY
MYOPATHIES
Distal Myopathies
Muscular Dystrophy, Duchenne
Phosphorylase Deficiency (McArdle Disease)

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn